Should LDL be called “bad” Cholesterol?
Dr. Nadir Ali
Cardiologist Dr. Nadir Ali challenges the idea of LDL as “bad cholesterol,” examining whether statin drugs truly prevent heart disease or may actually increase risks like diabetes, cancer, and vascular calcification, especially in the context of metabolic health and low-carb lifestyles.
Dr. Nadir Ali, an interventional cardiologist, explains how cholesterol and lipoproteins perform critical functions in immunity, hormone production, vitamin transport, membrane integrity, energy delivery, and vascular health, arguing that LDL is a vital participant rather than a simple villain. He reviews genetic conditions where LDL is absent and shows these patients suffer from infections, neurologic problems, fatty liver, and early death, suggesting that eliminating LDL is harmful. Ali then details how statins block cholesterol synthesis high in the biochemical pathway, reducing not only cholesterol but also intermediates needed for CoQ10, vitamin K2 activation, insulin receptor processing, antioxidant enzymes, and DNA repair, which he links to clinical findings of higher diabetes rates, muscle problems, heart failure, cancer, and vascular calcification in several observational and clinical datasets. He criticizes industry-sponsored statin and PCSK9 inhibitor trials for using relative risk reductions, selective reporting, and conflicted oversight to exaggerate modest absolute mortality benefits (for example, about 0.6 percent per year in early simvastatin trials) while downplaying harms. Overall, he urges physicians and patients to question LDL‑centric guidelines, recognize the potential for statins and PCSK9 inhibitors to act as “mitochondrial toxins” in some individuals, and focus instead on informed consent, metabolic health, and independent critical thinking about cardiovascular risk.
Summary
- Cholesterol and lipoproteins (including LDL) have many biologic roles: host defense, inflammation modulation, cell membrane structure, hormone production, fat‑soluble vitamin delivery, energy transport, and vascular calcification control.
- Genetic absence of LDL (abetalipoproteinemia) leads to failure to thrive, recurrent infections, blindness, neuromuscular problems, fatty liver, and early death, which Ali presents as evidence that LDL is essential rather than inherently “bad.”
- Statins block cholesterol synthesis high in the mevalonate pathway, reducing intermediates needed for CoQ10, vitamin K2 activation, antioxidant enzymes, insulin receptor processing, and glucose transport, potentially promoting insulin resistance, diabetes, muscle dysfunction, and oxidative stress.
- Ali cites observational data (for example, Women’s Health Initiative and Japanese registry analyses) suggesting higher diabetes incidence, more vascular calcification progression, and increased all‑cause mortality and cancer when cholesterol is aggressively lowered with statins.
- He argues that the most favorable statin trial (4S) showed only modest absolute mortality reduction (around 0.6 percent per year) despite large relative risk reductions that were heavily promoted in marketing.
- Industry sponsorship, conflicted trial committees, selective publication, and reliance on relative instead of absolute risk are presented as systemic problems that bias statin and PCSK9 inhibitor evidence in favor of drug benefits.
- PCSK9 inhibitors, which drive LDL to extremely low levels, are described as potentially harmful because they may remove LDL’s infection‑fighting and repair functions; Ali highlights a large trial where all‑cause mortality was numerically higher in the PCSK9 group despite dramatic LDL lowering.
- He concludes that physicians must reclaim critical thinking, fully disclose statin risks and modest benefits, and reconsider LDL‑centric guidelines in light of metabolic health, evolutionary biology, and the possibility that overtreatment with cholesterol‑lowering drugs may increase overall mortality in some populations.
Video Description
Dr. Nadir Ali is an interventional cardiologist with over 25 years of experience. He is also the chairman of the Department of Cardiology at Clear Lake Regional Medical Center. Before working as a cardiologist, he served as an assistant professor of medicine for eight years at Baylor College of Medicine in Houston, where he also received his medical training.
Dr. Ali has championed many aspects of the science and practice of a low-carb lifestyle in the local Clear Lake area since 2013. He organises a monthly nutritional seminar in the Searcy Auditorium of the Clear Lake Hospital that receives more than 100 visitors every month from the local community. Dr Ali’s focus is on managing heart disease, obesity, metabolic syndrome and diabetes.
Please consider supporting Low Carb Down Under via Patreon. A small monthly contribution will assist in the costs of filming and editing these presentations and will allow us to keep producing high quality content free from advertising. For further information visit; https://www.patreon.com/lowcarbdownunder
Transcript Summary
Cholesterol and Lipoproteins Are Multifunctional
Ali begins by disclosing that he does prescribe statins at times and is not giving individual medical advice, then explains that fat and cholesterol are waxy substances that do not dissolve in blood and must be transported in lipoprotein particles. These particles have protein “tags” that give them distinct functions, and he emphasizes that millions of years of evolutionary engineering have shaped lipoproteins to perform critical roles such as host defense, bacterial toxin clearance, inflammation modulation, cholesterol transport and excretion, and cell repair after injury.
Critical Roles of Cholesterol in Hormones, Vitamins, and Membranes
He goes on to list additional functions: cholesterol‑rich domains are required for insulin receptor structure and signaling, LDL delivers raw materials for sex hormone production, and lipoproteins carry fat‑soluble vitamins including those involved in energy delivery and vascular health. Cholesterol is also necessary for converting vitamin K1 to K2, which helps prevent vascular calcification, and for maintaining membrane integrity in cholesterol‑rich microdomains where receptors such as the insulin receptor and glucose transporter operate effectively.
Lessons from Absent LDL and Why LDL Is Not “Bad”
To illustrate LDL’s importance, Ali describes a genetic condition, abetalipoproteinemia, in which LDL is essentially absent and patients do not thrive, suffer recurrent infections, develop blindness and neuromuscular problems, accumulate fatty liver, and often die in their third or fourth decade. He contrasts this natural experiment with modern attempts to pharmacologically suppress LDL, arguing that ignoring nature’s warning leads to unintended consequences when we “interfere” with lipoproteins that have many vital functions.
How Statins Block Cholesterol and Its Intermediates
Ali explains that the body produces roughly 3,000 milligrams of cholesterol daily even if dietary intake is zero, demonstrating its biological importance and the presence of dedicated synthetic machinery. Statins inhibit cholesterol synthesis high in the biosynthetic cascade, reducing not only cholesterol but also intermediates like isopentenyl, CoQ10 (CoQ10), dolichol, and prenylated proteins that provide antioxidant protection, convert vitamin K1 to K2, support muscle function, process the insulin receptor, and maintain membrane structure.
Cholesterol Intermediates, Insulin Resistance, and Diabetes
He repeatedly returns to the theme that cholesterol intermediates are deeply involved in insulin receptor function: the receptor resides in a cholesterol‑rich caveola to signal correctly, dolichol attaches necessary sugar residues for receptor function, and the GLUT4 glucose channel depends on prenylated proteins derived from the same pathway. When statins deplete these intermediates, he argues, insulin signaling is impaired, contributing to insulin resistance, and he links this mechanistic view to clinical data from the Women’s Health Initiative showing higher diabetes incidence among women on statins versus those not taking them, with greater risk in Hispanic and Asian subgroups.
CoQ10 Depletion, Muscle Dysfunction, and Energy Failure
Using the analogy of CoQ10 as the “spark plug” of mitochondria, Ali says that without CoQ10 the engine cannot burn fuel and generate ATP. He cites a small study by Dr. Lance Jonas (he refers to “Lance Joan”) in which statin‑treated patients compared to matched controls had higher blood pressure and blood sugar, lower muscle CoQ10, lower antioxidant enzymes, impaired oxidative metabolism, and insulin resistance on muscle biopsy and blood work, supporting the idea that statins compromise mitochondrial function.
Statin Side Effects: Myalgias, Heart Failure, and Incomplete Reversibility
Ali describes a clinic series of 328 statin‑treated patients where about 50 reported myalgias, fatigue, shortness of breath, and memory issues; stopping statins led to improvement in many, but not all, cases. In a subset with heart muscle dysfunction on echocardiogram, discontinuation improved function in about half, but the other half did not improve, which he interprets as evidence that statin‑related damage can be only partially reversible in some patients.
Observational Heart Failure and Japanese Cohort Data
He criticizes an observational study claiming statins improve mortality in heart failure patients by arguing that comparing statin users to non‑users is unfair because high cholesterol itself predicts better survival in heart failure. When patients are stratified by statin adherence, he notes that those taking statins most frequently had the highest mortality, stroke, and heart attack rates, suggesting harm rather than benefit, and he presents Japanese cohort data where more aggressive cholesterol lowering with simvastatin was associated with higher all‑cause mortality, cancer, stroke, and diabetes incidence.
Cancer, DNA Repair, and Cholesterol Intermediates
Ali connects cholesterol intermediates to antioxidant defense and DNA repair mechanisms that help prevent cancer, arguing that depleting them could increase malignancy risk. He cites a pravastatin trial in older adults where cholesterol was reduced by about one‑third over three years and notes a statistically significant increase in cancer cases in the statin group, framing this as evidence that long‑term interference with cholesterol biology may elevate cancer risk.
Industry‑Funded Trials, Relative Risk, and Conflicts of Interest
He devotes a section to how industry‑sponsored clinical trials are structured, pointing out that 95 percent of statin studies are funded by manufacturers, with company payments flowing to trial sites, central adjudication committees, data safety monitoring boards, medical journals (through reprints), professional societies, and key opinion leaders. He argues that this network of financial relationships creates bias in design, analysis, and reporting, and notes historical issues like the Vioxx case in which Merck was found to have concealed cardiovascular harms, leading to tens of thousands of heart attacks and deaths and prompting new trial registration requirements.
Absolute vs Relative Risk and the 4S Trial
Ali reviews the landmark 4S simvastatin trial in about 4,000 Scandinavian patients, stating that the absolute mortality reduction was approximately 0.6 percent per year over five years, which he describes as modest. He contrasts this with the widely advertised 42 percent relative risk reduction and uses a lottery analogy to show how relative figures can make tiny absolute benefits sound dramatic, urging clinicians and patients to focus on absolute risk reduction when evaluating statin therapy.
Diminishing or Absent Mortality Benefits in Later Trials
He displays a timeline of major statin and PCSK9 trials from 1994 to 2017, showing that though LDL lowering increased (some trials reducing LDL by 50–60 percent), mortality benefits shrank or disappeared, particularly after more stringent trial reporting rules were implemented. In some later studies like FOURIER (a PCSK9 inhibitor trial), he notes that despite extreme LDL lowering to around 30 mg/dL, all‑cause mortality was slightly higher in the treatment arm, which he interprets as evidence that pushing LDL very low does not translate into better survival and may be harmful.
PCSK9, Acute Phase Response, and LDL’s Protective Role
Ali explains that PCSK9 is an acute‑phase reactant that downregulates LDL receptors on the liver during infection, raising circulating LDL to help fight pathogens, modulate inflammation, repair cells, and supply energy. By blocking PCSK9, he argues, we prevent this adaptive response, drive LDL to extremely low levels, and potentially remove LDL’s protective functions at times when the body needs them most.
Vascular Calcification, Vitamin K2, and Statins
Returning to vitamin K2, he notes that cholesterol intermediates help convert K1 to K2 and activate proteins that prevent calcium deposition in arteries. He references a VA study in which patients with high statin exposure had more rapid progression of coronary artery calcification over several years than those using statins less frequently, suggesting that long‑term statin use may worsen vascular calcification despite lowering LDL.
Cell Culture Evidence of Statin Toxicity
Ali shows a cell culture experiment where vascular smooth muscle cells exposed to increasing statin doses exhibited more cell death, with microscopy images showing damaged cells at higher concentrations. He uses this in vitro result as visual support for his argument that statins can be directly toxic to vascular cells, potentially contributing to plaque instability or other vascular problems when used chronically.
HDL, CETP Inhibition, and Unexpected Harms
He briefly discusses a trial where a CETP inhibitor raised HDL to very high levels and lowered LDL dramatically, producing a lipid profile many cardiologists would consider ideal. However, the high‑HDL, low‑LDL group experienced more deaths, more cancer mortality, more heart failure hospitalizations, more infections, and more strokes, which he presents as another example that manipulating cholesterol numbers without understanding the underlying biology can lead to worse outcomes.
Institutional Incentives and Physician Responsibility
Ali outlines how pharmaceutical companies recruit physicians as paid speakers and opinion leaders, sometimes paying hundreds of thousands of dollars annually, and urges viewers to search databases like ProPublica to see these financial ties. He argues that physicians, medical societies such as the American Heart Association and American College of Cardiology, journals, and regulators like the FDA are all influenced by industry money, and that this environment encourages aggressive statin and PCSK9 prescribing while downplaying alternative approaches.
Clinical Takeaways and Call for Critical Thinking
In his closing, Ali summarizes his concerns: he believes statins can function as mitochondrial toxins, impair memory and cognition, promote vascular calcification, induce insulin resistance, increase oxidative injury, and damage muscles, all while being supported by trials with significant industry conflicts. He calls on physicians to practice genuine informed consent, to discuss both risks and modest benefits with patients, and to reclaim clinical judgment rather than deferring to guidelines, key opinion leaders, or pharmaceutical marketing, concluding that the medical system may be contributing to mortality by over‑relying on these drugs.
